

Ajay K Nooka

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9175783/ajay-k-nooka-publications-by-citations.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

204
papers

5,178
citations

29
h-index

69
g-index

227
ext. papers

6,582
ext. citations

4.3
avg, IF

5.25
L-index

#	Paper	IF	Citations
204	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016 , 375, 754-66	59.2	965
203	Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. <i>Journal of Bone and Mineral Research</i> , 2008 , 23, 826-36	6.3	466
202	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology, The</i> , 2020 , 21, 207-221	21.7	281
201	Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. <i>Haematologica</i> , 2013 , 98, 1753-61	6.6	267
200	Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019 , 381, 727-738	59.2	266
199	Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. <i>Nature Communications</i> , 2018 , 9, 5341	17.4	227
198	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology, The</i> , 2014 , 15, 333-42	21.7	206
197	Daratumumab plus bortezomib and dexamethasone bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. <i>Haematologica</i> , 2018 , 103, 2079-2087	6.6	167
196	Treatment options for relapsed and refractory multiple myeloma. <i>Blood</i> , 2015 , 125, 3085-99	2.2	116
195	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 859-866	2.2	100
194	Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. <i>Cancer</i> , 2011 , 117, 2530-40	6.4	96
193	Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. <i>Cancer</i> , 2005 , 103, 749-55	6.4	95
192	A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. <i>Clinical Cancer Research</i> , 2010 , 16, 5079-86	12.9	82
191	Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. <i>Annals of Oncology</i> , 2013 , 24, 441-448	10.3	63
190	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016 , 91, 575-80	7.1	60
189	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. <i>Blood Cancer Journal</i> , 2019 , 9, 94	7	59
188	Daratumumab in multiple myeloma. <i>Cancer</i> , 2019 , 125, 2364-2382	6.4	58

187	Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. <i>Blood</i> , 2017 , 129, 1969-1979	2.2	57
186	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1928-1937	2.2	56
185	Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. <i>JCI Insight</i> , 2019 , 5,	9.9	55
184	Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. <i>Nature Communications</i> , 2019 , 10, 1911	17.4	53
183	Daratumumab (anti-CD38) induces loss of CD38 on red blood cells. <i>Blood</i> , 2017 , 129, 3033-3037	2.2	47
182	Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. <i>Cancer</i> , 2019 , 125, 2991-3000	6.4	47
181	Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, e183267	13.4	45
180	In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy. <i>Journal of Biological Chemistry</i> , 2015 , 290, 14441-53	5.4	40
179	Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. <i>Ophthalmology and Therapy</i> , 2020 , 9, 889-911	5	35
178	Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. <i>Cancer</i> , 2013 , 119, 4119-28	6.4	33
177	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , 2020 , 34, 2430-2440	10.7	30
176	Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor. <i>Blood</i> , 2016 , 128, 1150-1150	2.2	29
175	A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2019 , 68, 196-203	11.6	28
174	Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2016 , 128, 2142-2142	2.2	28
173	Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. <i>Cancer</i> , 2010 , 116, 3143-51	6.4	27
172	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. <i>Haematologica</i> , 2020 , 105, 468-477	6.6	27
171	Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. <i>Blood Cancer Journal</i> , 2019 , 9, 3	7	26
170	High-risk Multiple Myeloma: Definition and Management. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17S, S80-S87	2	26

169	Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 852-857	4.7	25
168	Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. <i>Nature Communications</i> , 2020 , 11, 1228	17.4	24
167	DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8502-8502	2.2	23
166	Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. <i>Cancer</i> , 2021 , 127, 4198-4212	6.4	23
165	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. <i>Cancer</i> , 2019 , 125, 416-423	6.4	22
164	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2071-6	1.9	21
163	Development of GLUT4-selective antagonists for multiple myeloma therapy. <i>European Journal of Medicinal Chemistry</i> , 2017 , 139, 573-586	6.8	21
162	Clinical Efficacy of Daratumumab, Pomalidomide and Dexamethasone in Relapsed, Refractory Myeloma Patients: Utility of Retreatment with Daratumumab Among Refractory Patients. <i>Blood</i> , 2016 , 128, 492-492	2.2	21
161	Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. <i>Leukemia</i> , 2019 , 33, 1291-1296	10.7	20
160	Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study. <i>Blood</i> , 2016 , 128, 491-491	2.2	20
159	Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8536-8536	2.2	20
158	Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , 2018 , 124, 4342-4349	6.4	20
157	Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab. <i>Journal of Oncology Practice</i> , 2018 , 14, 414-422	3.1	19
156	DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020 , 136, 19-20	2.2	18
155	Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation. <i>Oncotarget</i> , 2016 , 7, 59727-59741	3.3	18
154	Bilateral adrenal hemorrhage: an overlooked cause of hypotension. <i>Journal of Emergency Medicine</i> , 2007 , 32, 167-9	1.5	15
153	Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study). <i>Blood</i> , 2016 , 128, 3307-3307	2.2	15
152	BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. <i>Oncotarget</i> , 2016 , 7, 27753-63	3.3	15

151	Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1393-5	4.7	14
150	Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor. <i>Blood</i> , 2019 , 134, 3192-3192	2.2	14
149	Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. <i>JCI Insight</i> , 2020 , 5,	9.9	13
148	Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low FcγR1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study. <i>Blood</i> , 2013 , 122, 285-285	2.2	13
147	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma 2020 , 8,		13
146	A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1609-1614	4	13
145	Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib. <i>Biologics: Targets and Therapy</i> , 2013 , 7, 13-32	4.4	12
144	An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8002-8002	2.2	12
143	Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. <i>Cancer Biology and Therapy</i> , 2016 , 17, 769-77	4.6	11
142	Description of the types and content of phase 1 clinical trial consent conversations in practice. <i>Clinical Trials</i> , 2015 , 12, 567-74	2.2	11
141	MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013 , 122, 1969-1969	2.2	11
140	Bortezomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (V-DCEP) for the Treatment of Multiple Myeloma. <i>Blood</i> , 2014 , 124, 2139-2139	2.2	11
139	Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. <i>Blood</i> , 2021 , 137, 3604-3615	2.2	11
138	New Targets and New Agents in High-Risk Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, e431-41	7.1	11
137	Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial. <i>Blood</i> , 2014 , 124, 32-32	2.2	10
136	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). <i>Blood</i> , 2015 , 126, 3036-3036	2.2	10
135	Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021 , 138, 896-896	2.2	10
134	Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). <i>Blood Cancer Journal</i> , 2021 , 11, 103	7	10

133	KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2021 , 11, 116	7	10
132	Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study. <i>Infection Control and Hospital Epidemiology</i> , 2017 , 38, 651-657	2	9
131	Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participation. <i>Cancer</i> , 2016 , 122, 3207-3214	6.4	9
130	CD86 regulates myeloma cell survival. <i>Blood Advances</i> , 2017 , 1, 2307-2319	7.8	9
129	Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM. <i>Blood</i> , 2018 , 132, 598-598	2.2	9
128	New Targets and New Agents in High-Risk Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 36, e431-e441	7.1	9
127	Myeloma Is Not a Single Disease. <i>Journal of Oncology Practice</i> , 2016 , 12, 287-92	3.1	9
126	Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma. <i>Future Oncology</i> , 2018 , 14, 3111-3121	3.6	8
125	Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies. <i>Blood</i> , 2018 , 132, 3288-3288	2.2	8
124	Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. <i>Future Oncology</i> , 2021 , 17, 1987-2003	3.6	8
123	Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 383-9	1.9	7
122	From single nucleotide polymorphisms to constant immunosuppression: mesenchymal stem cell therapy for autoimmune diseases. <i>BioMed Research International</i> , 2013 , 2013, 929842	3	7
121	The importance of complete response in outcomes in myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2009 , 15, 465-72	2.2	7
120	DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8519-8519	2.2	7
119	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. <i>Blood Cancer Journal</i> , 2020 , 10, 40	7	7
118	Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor. <i>Blood</i> , 2018 , 132, 3270-3270	2.2	6
117	Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020 , 136, 26-27	2.2	6
116	Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study. <i>Blood</i> , 2012 , 120, 336-336	2.2	6

115	Changing Epidemiology and Improved Survival In Patients With Waldenstrom Macroglobulinemia: Review Of Surveillance, Epidemiology, and End Results (SEER) Data. <i>Blood</i> , 2013 , 122, 3135-3135	2.2	6
114	Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare. <i>Blood Cancer Discovery</i> , 2021 , 2, 119-124	7	6
113	Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, S249-S250	2	6
112	Sequential or combination therapy for multiple myeloma. <i>Expert Review of Hematology</i> , 2012 , 5, 533-45	2.8	5
111	Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2015 , 126, 4241-4241	2.2	5
110	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. <i>Blood Advances</i> , 2020 , 4, 181-190	7.8	5
109	Is Maintenance Therapy for Everyone?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16 Suppl, S139-44	4	4
108	Novel combination approaches for myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2015 , 2015, 286-93	3.1	4
107	Improving induction therapy in multiple myeloma. <i>Current Hematologic Malignancy Reports</i> , 2010 , 5, 119-28	2.8	4
106	Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas. <i>Blood</i> , 2019 , 134, 3140-3140	2.2	4
105	Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis. <i>Blood</i> , 2011 , 118, 1855-1855	2.2	4
104	Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL). <i>Blood</i> , 2011 , 118, 775-775	2.2	4
103	Colesevelam Hydrochloride for the Treatment of Lenalidomide Induced Diarrhea. <i>Blood</i> , 2014 , 124, 5779-5779	2.5	4
102	DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021 , 138, 897-897	2.2	4
101	Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200088	2.2	4
100	Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2019 , 25, 19-31	2.2	3
99	RVD is a Superior Induction Regimen Compared to VCD Among Transplant-Eligible Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, e137-e138	2	3
98	Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. <i>Transfusion</i> , 2015 , 55, 2351-7	2.9	3

97	Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, e59-63	2	3
96	Clinical use of rituximab in patients with HIV related lymphoma and Multicentric Castleman's disease. <i>Current Drug Delivery</i> , 2012 , 9, 41-51	3.2	3
95	Supportive therapies in multiple myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 971-9	7.3	3
94	Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma. <i>Blood</i> , 2018 , 132, 952-952	2.2	3
93	Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). <i>Blood</i> , 2014 , 124, 4737-4737	2.2	3
92	Safety and efficacy of daratumumab-based regimens in elderly (≥5 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8033-8033	2.2	3
91	Primary refractory multiple myeloma: a real-world experience with 85 cases. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2868-2875	1.9	3
90	Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 797-803 ²		3
89	Downregulation of PA28 β induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. <i>Blood Cancer Journal</i> , 2020 , 10, 125	7	3
88	Selinexor for the treatment of patients with previously treated multiple myeloma. <i>Expert Review of Hematology</i> , 2021 , 14, 697-706	2.8	3
87	Safety and survival outcomes for bloodless transplantation in patients with myeloma. <i>Cancer</i> , 2019 , 125, 185-193	6.4	3
86	Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. <i>American Journal of Hematology</i> , 2021 , 96, E68-E71	7.1	3
85	Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma. <i>Journal of Oncology Practice</i> , 2018 , 14, 561-564	3.1	3
84	Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites. <i>Cancer</i> , 2018 , 124, 4358-4365	6.4	3
83	Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102257	2.2	3
82	Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. <i>JCO Oncology Practice</i> , 2020 , 16, e1169-e1180	2.3	2
81	Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. <i>Blood</i> , 2018 , 132, 3282-3282	2.2	2
80	Efficacy of Induction Therapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2018 , 132, 3294-3294	2.2	2

79	Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 5647-5647	2.2	2
78	Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study. <i>Blood</i> , 2019 , 134, 1872-1872	2.2	2
77	The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs). <i>Blood</i> , 2011 , 118, 3994-3994	2.2	2
76	Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry. <i>Blood</i> , 2012 , 120, 2072-2072	2.2	2
75	Transcriptional and Post-Translational Regulation Of The Bcl-2 Family By IL-6 Mediates Resistance To ABT-737 In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1924-1924	2.2	2
74	Efficacy Of ABT-199 In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 4453-4453	2.2	2
73	Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). <i>Blood</i> , 2015 , 126, 4246-4246	2.2	2
72	B-Cell Markers Predict Response to Venetoclax in Multiple Myeloma. <i>Blood</i> , 2016 , 128, 2108-2108	2.2	2
71	Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). <i>Blood</i> , 2016 , 128, 2124-2124	2.2	2
70	MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8584-8584	2.2	2
69	Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. <i>EJHaem</i> , 2021 , 2, 375-384	0.9	2
68	Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. <i>British Journal of Haematology</i> , 2021 , 194, 784-788	4.5	2
67	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. <i>Blood Cancer Discovery</i> , 2021 , 2, 600-615	7	2
66	Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients. <i>Cancer</i> , 2015 , 121, 853-62	6.4	1
65	TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma. <i>Blood Advances</i> , 2017 , 1, 1848-1853	7.8	1
64	Carfilzomib 56mg/m2 Twice-Weekly in Combination with Dexamethasone and Daratumumab (KdD) Versus Daratumumab in Combination with 8 Cycles of Bortezomib and Dexamethasone (DVd); A Matching-Adjusted Indirect Treatment Comparison. <i>Blood</i> , 2020 , 136, 8-9	2.2	1
63	Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. <i>Blood</i> , 2018 , 132, 3241-3241	2.2	1
62	Oncolytics Virus Replication Using Pelareorep (Reolysin) and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses. <i>Blood</i> , 2018 , 132, 2655-2655	2.2	1

61	Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy. <i>Blood</i> , 2018 , 132, 1884-1884	2.2	1
60	Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 2157-2157	2.2	1
59	Osteonecrosis of the Jaw or Maxilla after Intravenous Bisphosphonates for Multiple Myeloma and Breast Cancer: Long-Term Follow-Up Shows a Slow Rate of Healing.. <i>Blood</i> , 2006 , 108, 5121-5121	2.2	1
58	Impact of Body Mass Index (BMI) On Overall Survival in Myeloma. <i>Blood</i> , 2012 , 120, 4289-4289	2.2	1
57	Vorinostat, Bortezomib, Cyclophosphamide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients. <i>Blood</i> , 2014 , 124, 5773-5773	2.2	1
56	Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs). <i>Blood</i> , 2015 , 126, 5344-5344	2.2	1
55	HLA Haplotypes Are Associated with Multiple Myeloma Risk in the African American Multiple Myeloma Study (AAMMS). <i>Blood</i> , 2016 , 128, 3250-3250	2.2	1
54	Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8540-8540	2.2	1
53	Incidence and geographic distribution of adult acute leukemia in the state of Georgia. <i>Southern Medical Journal</i> , 2014 , 107, 497-500	0.6	1
52	Thromboembolic Events (TEE) with Lenalidomide-Based Therapies for Multiple Myeloma (MM): Emory Experience.. <i>Blood</i> , 2009 , 114, 3888-3888	2.2	1
51	Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County Hospital. <i>Journal of Stem Cell Research & Therapy</i> , 2016 , 6,	1	1
50	Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021 , 27, 3178-3189	12.9	1
49	A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. <i>Blood Cancer Journal</i> , 2021 , 11, 149	7	1
48	Moving Toward a Cure for Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022 , 1-12	7.1	1
47	Safety and Efficacy of Evomela in Myeloma Autotransplants. <i>Blood</i> , 2018 , 132, 3446-3446	2.2	0
46	Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401). <i>Blood</i> , 2021 , 138, 899-899	2.2	0
45	Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. <i>Transplantation and Cellular Therapy</i> , 2021 , 28, 75.e1-75.e1		0
44	Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. <i>British Journal of Haematology</i> , 2021 , 193, 561-569	4.5	0

43	Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.. <i>Blood Cancer Journal</i> , 2022 , 12, 63	7	o
42	Autologous hematopoietic transplant in multiple myeloma 2017 , 194-206		
41	Meningeal Myelomatosis. <i>Journal of Oncology Practice</i> , 2016 , 12, 187-8	3.1	
40	Role of clonoSEQ , a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma. <i>Blood</i> , 2020 , 136, 50-51	2.2	
39	A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. <i>American Journal of Cancer Research</i> , 2021 , 11, 3285-3293	4.4	
38	Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients. <i>Blood</i> , 2021 , 138, 1616-1616	2.2	
37	BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction. <i>Blood</i> , 2021 , 138, 1624-1624	2.2	
36	Impact of Platelet Transfusion on Pulmonary Function of Hematology Oncology Patients: The Piper Study. <i>Blood</i> , 2021 , 138, 1077-1077	2.2	
35	Mitochondrial Electron Transport Chain Inhibition Promotes Resistance to Proteasome Inhibitors in Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1611-1611	2.2	
34	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR). <i>Blood</i> , 2021 , 138, 2758-2758	2.2	
33	Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. <i>Blood</i> , 2018 , 132, 3302-3302	2.2	
32	The Impact of a Physical Activity Intervention Can be Accurately Assessed By Smart Watches in Patients Completing Autologous Stem Cell Transplantation for Lymphoma or Multiple Myeloma: Results of a Feasibility Study. <i>Blood</i> , 2018 , 132, 5911-5911	2.2	
31	Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy. <i>Blood</i> , 2018 , 132, 405-405	2.2	
30	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR). <i>Blood</i> , 2018 , 132, 2011-2011	2.2	
29	The Role of Proteasome Activator PA28 in Multiple Myeloma. <i>Blood</i> , 2019 , 134, 5499-5499	2.2	
28	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR). <i>Blood</i> , 2019 , 134, 3188-3188	2.2	
27	Outcomes for Myeloma in the Era of Lenalidomide Maintenance Are Not Different Among Ethnic Groups Following Autologous Transplant. <i>Blood</i> , 2014 , 124, 3973-3973	2.2	
26	Dexamethasone Synergizes with ABT-199 through the Induction of Bim and Bcl-2 Dependence in Myeloma. <i>Blood</i> , 2014 , 124, 3447-3447	2.2	

- 25 Racial Disparity in Patients with Multiple Myeloma Are Blunted in the Era Novel Therapies. *Blood*, **2014**, 124, 2525-2525 2.2
- 24 Risk Factors for Development of Myeloma: Role of Smoking and Alcohol. *Blood*, **2014**, 124, 2604-2604 2.2
- 23 Ablation of CD28-86 Signaling Results in Induction of Both Caspase-Dependent and Caspase-Independent Cell Death in Myeloma Cells. *Blood*, **2014**, 124, 4726-4726 2.2
- 22 Solitary Plasmacytoma Incidence, Mortality, and Survival Trends in the United States. *Blood*, **2015**, 126, 5629-5629 2.2
- 21 Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT). *Blood*, **2015**, 126, 4202-4202 2.2
- 20 Racial Disparities in Incidence and Survival for Patients with Multiple Myeloma in the United States. *Blood*, **2015**, 126, 4508-4508 2.2
- 19 The Role of County-Level Contextual Predictors in Multiple Myeloma Mortality. *Blood*, **2015**, 126, 3325-3325 2.2
- 18 Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant. *Blood*, **2016**, 128, 4524-4524 2.2
- 17 A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials. *Blood*, **2011**, 118, 3954-3954 2.2
- 16 Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis. *Blood*, **2011**, 118, 1959-1959 2.2
- 15 Management of Back Pain in Myeloma Patients Using Vertebral Augmentation: A Practical Approach to Elimination of Pain and Improvement of Functional Status. *Blood*, **2012**, 120, 4713-4713 2.2
- 14 Interleukin-6 Enhances the Survival of Myeloma Cells by Regulating Bim Binding to Anti-Apoptotic Bcl-2 Proteins. *Blood*, **2012**, 120, 4024-4024 2.2
- 13 Consolidation with High Dose Therapy and Autologous Stem Cell Transplant Improves Survival for Patients with Mantle Cell Lymphoma. *Blood*, **2012**, 120, 2006-2006 2.2
- 12 Outcomes of hematopoietic stem cell transplant recipients admitted to the medical intensive care unit. *Journal of Clinical Oncology*, **2013**, 31, 7035-7035 2.2
- 11 Access To Therapeutic Surgical Procedures For Pathologic Fractures In Multiple Myeloma Patients: Analysis of Nationwide Inpatient Sample (NIS). *Blood*, **2013**, 122, 1709-1709 2.2
- 10 Hospitalization Outcome Metrics Based On Payer Status In Myeloma Patients That Receive Autologous Stem Cell Transplant (ASCT). *Blood*, **2013**, 122, 5606-5606 2.2
- 9 Indications For Hospital Admissions and Outcomes Of Hospitalization Among Multiple Myeloma Patients In The U.S: Data From National Inpatient Sample. *Blood*, **2013**, 122, 5582-5582 2.2
- 8 P38 Is a Negative Regulator Of The Bortezomib-Induced Heat Shock Response In Multiple Myeloma. *Blood*, **2013**, 122, 1929-1929 2.2

7	Correlation Among Different Plasma Cell Disorders Markers and Immunoglobulin Heavy Light Chains (HLC). <i>Blood</i> , 2013 , 122, 3148-3148	2.2
6	Dual Inhibition Of Mcl-1 By The Combination Of Carfilzomib and TG02 In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 3171-3171	2.2
5	Using RNA-Seq, SNP-CN and Targeted Deep Sequencing To Improve The Diagnostic Paradigm In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1856-1856	2.2
4	Maintenance Strategies for Myeloma: Is Bigger Always Better?. <i>Cancer Journal (Sudbury, Mass)</i> , 2021 , 27, 231-238	2.2
3	32 Laboratory Evaluation for Therapy-Related Myeloid Neoplasia-Associated Changes After Autotransplant for Multiple Myeloma. <i>American Journal of Clinical Pathology</i> , 2018 , 149, S180-S180	1.9
2	How Does Genetics and MRD Impact Treatment or Doesn't It?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, S69-S72	2
1	Carfilzomib 56 mg/m twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison.. <i>Leukemia and Lymphoma</i> , 2022 , 1-10	1.9